-
The most common type 2 diabetes drug needs the action of a cellular-stress-response protein to make effect
Metformin, the most prescribed drug for treating diabetes mellitus, known as type 2 diabetes, requires the presence of the growth differentiation factor 15 (GDF15) -a protein whose expression increases in response to cellular stress- to present its antidiabetic effects.
-
Dr Alexandra Avgustinova awarded a scientific excellence grant from the European Research Council (ERC)
The ERC Starting Grant will fund the project "Oncogenic competence during development - When, Where and Why?" led by Dr Alexandra Avgustinova (IRSJD), with approximately 1.5 million euros.
-
Device developed to facilitate monitoring of hereditary and hepatic metabolic disorders
Drs. Rafael Artuch and Xavier Rosell, with the IRSJD, collaborate on a UAB research project, which has developed a new device capable of monitoring the patient's blood ammonium levels at any given time.
-
Relationship of environmental exposure to nitrogen oxide with the severity of rhinovirus infection
Researchers at Institut de Recerca Sant Joan de Déu (IRSJD) · SJD Barcelona Children's Hospital have found that exposure to higher concentrations of atmospheric nitrogen oxide in childhood is associated with greater severity of rhinovirus infection and a higher number of admissions to the Paediatric Intensive Care Unit.
-
Science4Pandemics presents two Citizen Science projects
The digital platform Science4Pandemics has launched two new citizen science projects for adolescents between 12 and 17 years old, as well as their parents, to collaborate with the project and provide real data for participatory research on vaccines and clinical trials.
-
First clinical guideline on Schaaf-Yang syndrome for professionals and families
Improving knowledge of the Schaaf-Yang syndrome (SYS) -an ultrarare disease caused by mutations in the MAGEL2 gene- is the aim of the first clinical guideline aimed at healthcare professionals and families of children affected by this pathology.
-
CDF15 cytokine, a promising therapeutic target against type 2 diabetes
A team led by Dr. Manuel Vázquez-Carrera, from the Institut de Recerca Sant Joan de Déu and professor Faculty of Pharmacy and Food Sciences and the Institute of Biomedicine (IBUB) of the UB, has conducted a review study on the Growth Differentiation Factor 15 (GDF15) -a protein expressed under physiological stress conditions- and its potential impact on the treatment for type 2 diabetes.
-
Scientists at IRSJD and IRB Barcelona develop a study model for Ewing sarcoma in the Drosophila fly
This novel model has come about from a close collaboration between the laboratories headed by Dr. Jaume Mora at Institut de Recerca Sant Joan de Déu (IRSJD) and SJD Barcelona Children’s Hospital, and Dr. Cayetano Gonzalez at the Institute for Research in Biomedicine (IRB Barcelona). The work has been published in the journal PNAS Nexus.
-
Institut de Recerca Sant Joan de Déu participes in a project that facilitates access to personalised medicine
Institut de Recerca Sant Joan de Déu and SJD Children’s Hospital is participating in the SEHOP-PENCIL project that aims to facilitate access to precision medicine for all children and adolescents with cancer in Spain, regardless of where they live.
